A new scientific report reveals that the protein aggregates associated with Parkinson’s disease are not inert clumps of ...
Researchers have devised a new way to illuminate the previously invisible oligomer clumps driving Parkinson’s disease.
A new study led by Rice University's Pernilla Wittung-Stafshede has revealed that protein clumps, or plaques that clog the ...
Researchers have finally seen and measured the tiny alpha-synuclein oligomers that may ignite Parkinson’s disease. With the ...
— Treatment of Parkinson's and Lewy body patient brain tissue with WTX-607 demonstrated highly specific binding to aggregates within neurons in patients' brain tissue and potent inhibition of ...
Researchers have designed a peptide that prevents the deadly misfolding of alpha-synuclein, the protein behind Parkinson’s and some dementias. In lab and animal tests, it stabilized the protein and ...
Parkinson’s disease is associated with the buildup of a particular brain protein that currently has no approved therapies addressing it. Novartis was among the companies pursuing this target, but its ...
University of California divulges new α-synuclein, amyloid-β protein and MAPT propagation inhibitors
The University of California has synthesized α-synuclein (SNCA) and/or amyloid-β protein and/or microtubule-associated protein tau (PHF-tau; MAPT) propagation inhibitors reported to be useful for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback